1. Home
  2. VIGL vs SFWL Comparison

VIGL vs SFWL Comparison

Compare VIGL & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • SFWL
  • Stock Information
  • Founded
  • VIGL 2020
  • SFWL 2001
  • Country
  • VIGL United States
  • SFWL China
  • Employees
  • VIGL N/A
  • SFWL N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • SFWL Trucking Freight/Courier Services
  • Sector
  • VIGL Health Care
  • SFWL Industrials
  • Exchange
  • VIGL Nasdaq
  • SFWL Nasdaq
  • Market Cap
  • VIGL 89.3M
  • SFWL 80.8M
  • IPO Year
  • VIGL 2022
  • SFWL 2023
  • Fundamental
  • Price
  • VIGL $2.76
  • SFWL $1.01
  • Analyst Decision
  • VIGL Strong Buy
  • SFWL
  • Analyst Count
  • VIGL 5
  • SFWL 0
  • Target Price
  • VIGL $21.00
  • SFWL N/A
  • AVG Volume (30 Days)
  • VIGL 2.7M
  • SFWL 21.7K
  • Earning Date
  • VIGL 03-25-2025
  • SFWL 03-27-2025
  • Dividend Yield
  • VIGL N/A
  • SFWL N/A
  • EPS Growth
  • VIGL N/A
  • SFWL N/A
  • EPS
  • VIGL N/A
  • SFWL 0.11
  • Revenue
  • VIGL N/A
  • SFWL $446,281,000.00
  • Revenue This Year
  • VIGL N/A
  • SFWL N/A
  • Revenue Next Year
  • VIGL N/A
  • SFWL N/A
  • P/E Ratio
  • VIGL N/A
  • SFWL $9.37
  • Revenue Growth
  • VIGL N/A
  • SFWL 14.80
  • 52 Week Low
  • VIGL $1.49
  • SFWL $0.81
  • 52 Week High
  • VIGL $6.06
  • SFWL $2.23
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 70.15
  • SFWL 46.13
  • Support Level
  • VIGL $2.54
  • SFWL $0.98
  • Resistance Level
  • VIGL $2.88
  • SFWL $1.06
  • Average True Range (ATR)
  • VIGL 0.22
  • SFWL 0.04
  • MACD
  • VIGL 0.03
  • SFWL 0.01
  • Stochastic Oscillator
  • VIGL 85.19
  • SFWL 44.00

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About SFWL Shengfeng Development Limited

Shengfeng Development Ltd is a holding company. The company offers contract logistics services comprising planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The integrated logistics solution services of the company are comprised of three segments: B2B freight transportation; cloud storage; and value-added services.

Share on Social Networks: